Pfizer divests certain Australian Fort Dodge assets to Virbac-GL
SYDNEY--Pfizer Animal Health today announced the completion of the previously-announced divestiture of certain Fort Dodge veterinary assets in Australia to Virbac (Australia) Pty Limited. The financial terms of the transaction were not disclosed.
Pfizer divested the assets in compliance with requirements imposed by the ACCC in connection with Pfizer’s acquisition of Wyeth, including the Fort Dodge business, by Pfizer in October 2009.
The assets acquired by Virbac consist of the Fort Dodge Australia livestock business, including a range of livestock vaccines and the Cydectin range of sheep and cattle parasiticides, along with a biologicals manufacturing facility at Penrith, NSW.
“This transaction is the final divestiture of assets required by the ACCC in relation to Pfizer Inc’s acquisition of Wyeth, including the Fort Dodge Animal Health Business,” said Mr Mike Van Blommestein, General Manager of Pfizer Animal Health in Australia.
“With the integration of Wyeth, including the Fort Dodge range of veterinary products, Pfizer’s animal health business remains the world’s leader in the discovery, development and manufacturing of veterinary vaccines and medicines for livestock and companion animals,” added Mr. Van Blommestein.
Pfizer Animal Health’s complete Australian portfolio now contains complementary livestock veterinary products in beef, swine and poultry production, as well as complementary companion animal veterinary products and a redefined equine portfolio.
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc, is a world leader in discovering and developing innovative animal prescription medicines and vaccines, investing an estimated $300 million annually. For more information on how Pfizer works to ensure a safe, sustainable global food supply with healthy livestock, or how Pfizer helps companion animals to live longer, healthier lives, visit animalhealth.pfizer.com.